Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

IsoRay Ships First GliaSite Brain Cancer Treatment

November 29, 2011 By AxoGen, Inc.

RICHLAND, Wash.–(BUSINESS
WIRE
)–IsoRay, Inc. announced it has shipped its first GliaSite® radiation therapy system. The Company initiated
sales after receiving final approval this week from the State of Washington
Department of Health to manufacture its GliaSite® radiation therapy system. The
GliaSite® radiation therapy system is a balloon catheter device used in the
treatment of brain cancer. Having already received FDA clearance, the Washington State
regulatory approval opened the door for sales of IsoRay’s GliaSite® brain
cancer treatment in the United
States.

IsoRay CEO Dwight Babcock says inquiries are on the rise,
“News of final regulatory approval has generated a great deal of interest
throughout the medical community in the U.S. and internationally. We are
hearing from physicians as well as brain cancer patients who are seeking treatment
options for Glioblastomas and metastasized brain cancers.”

The GliaSite® radiation system offers an innovative
alternative that presents an important advance over previous brain cancer
treatments. Doctors are able to use the system to directly place a specified
dosage of liquid radiation in areas where cancer is most likely to still remain
after completion of brain tumor removal. The ability to precisely place a
specified dosage of this form of radiation means there is less likelihood for
damage to occur to healthy brain tissue compared to other alternative
treatments. Importantly, the GliaSite® radiation treatment diminishes the
ability of the tumor to recur which means important benefits for patients in
longevity as well as quality of life.

The news comes as the Company is moving forward to achieve
FDA clearance of liquid Cesium-131 for use with the GliaSite® radiation system.
IsoRay is the exclusive manufacturer of Cesium-131 for cancer treatment. In its current form, the
pioneering brachytherapy treatment represents one of the most
important advancements in internal radiation therapy in 20 years. In other
developments, CEO Babcock revealed that discussions are already underway
regarding the application of Cesium-131 for treating cancers in other body
sites including breast and esophageal cancers.

Babcock says he views the latest developments as just the
beginning of important benefits from GliaSite® for the company, too. “We
expect GliaSite® to be a tremendous revenue generator. It is my sense that it
will fuel other important opportunities for IsoRay’s growth and
expansion.”

IsoRay holds exclusive worldwide distribution rights for the
GliaSite® radiation therapy system as well as exclusive worldwide licensing
rights to Iotrex®, a liquid iodine radiation for use in brain cancer treatment.
Prior to the Company’s acquisition of the GliaSite® technology, approximately
500 GliaSite® cases were performed annually at some 40 hospitals worldwide.

The GliaSite® system has established reimbursement for both
in-patient and out-patient settings. In addition to its CMS codes, Cesium-131
is FDA-cleared in seed form for the treatment of prostate cancer, lung cancer, ocular melanoma cancer, brain cancer, colorectal cancer,
gynecologic cancer, and head and neck cancer and other cancers throughout the body.

About IsoRay

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole
producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy
options throughout the body. Learn more about this innovative Richland, Washington
company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.

Posted by Sean Fenske, Editor-in-Chief, MDT

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech